Biotechnology
- 4669.241
- +49.141+1.06%
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint
Ionis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 18.2% Needham $60 → $60 Reiterates Buy → Buy 07/16/2024 31.99% B of A Securities $64 → $67
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.
Valneva Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 235.92% HC Wainwright & Co. $26 → $26 Reiterates Buy → Buy 06/28/2024 235.92% HC Wainwright &
ATyr Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 1958.82% HC Wainwright & Co. $35 → $35 Reiterates Buy →
Kiniksa Pharmaceuticals Q2 2024 Earnings Preview
Kezar Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 993.75% HC Wainwright & Co. $20 → $7 Maintains Buy 05/10/2024 3025% HC Wainwright & Co. $20 → $
Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials
On Monday, Rick Barry, the executive chairman of Cassava Sciences Inc (NASDAQ:SAVA), wrote a letter to shareholders and employees.He said the company is in the final stages of testing its Alzheimer'
Needham Starts Axsome at Buy, Cites Revenue Growth Potential
NuCana Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 5036.99% Oppenheimer $4 → $150 Maintains Outperform 04/01/2024 36.99% Oppenheimer $4 → $4
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG (OTC:RHHBY), Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE)
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday's session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their
Allarity Therapeutics Hit By SEC Notice Related Disclosures Of Once Lead Cancer Program
Allarity Therapeutics Inc (NASDAQ:ALLR) revealed on Monday it received a "Wells Notice" from the U.S. Securities and Exchange Commission (SEC).This notice pertains to the company's disclosures about
IBio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 68.22% Brookline Capital → $3.6 Initiates Coverage On → Buy 06/03/2024 133.63% Chardan
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
14 analysts have shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:RARE) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table
How Is The Market Feeling About Iovance Biotherapeutics?
Iovance Biotherapeutics's (NYSE:IOVA) short percent of float has risen 3.31% since its last report. The company recently reported that it has 56.42 million shares sold short, which is 22.5% of all
Alliance Global Partners Maintains Buy on Tonix Pharmaceuticals, Raises Price Target to $11
Alliance Global Partners analyst James Molloy maintains Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy and raises the price target from $6 to $11.
Tonix Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 1833.22% Alliance Global Partners $6 → $11 Maintains Buy 02/28/2024 427.24% Dawson James → $3